DNX Corp. of Princeton, N.J., has obtained rights to bloodsubstitute cross-linking technologies from Columbia Universityand the University of Maryland, Baltimore. Terms were notdisclosed.

The company also has begun a clinical pilot purification plantand a new swine production facility capable of producingsufficient quantities of DNX's blood substitute product throughPhase I studies.

The company estimated its combined capital investment forconstruction at about $5 million and projects that the plant willbegin production in spring 1993.

It said it will submit an investigational new drug application tobegin testing of its blood substitute product during 1994.

(c) 1997 American Health Consultants. All rights reserved.